

**ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQSE GROWTH MARKET****APPLICANT NAME:**

Cardiogeni PLC

**APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:**

Registered office address: Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford-Upon-Avon, England, CV37 7GZ

Phone Number: 0 1789 576047

**DIRECTORS AND PROPOSED DIRECTORS:**

- Darrin Disley, Executive Chairman
- Ajan Reginald, Executive Officer
- Professor Sir Martin Evans, Chief Scientific Officer
- Chaim Hurvitz, Independent Non-Executive Director
- Professor Joanne Martin, proposed Independent Non-Executive Director

**APPLICANT SECTOR:**

Health care

**DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:**

Founded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group's platform technology enables the creation of unique (living) cells that are engineered with a therapeutic function.

The Group's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. The Group's novel technology was developed in-house by Professor Sir Martin Evans and is protected by a portfolio of ~100 international patents and trademarks.

CLXR-001 targets heart failure and consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration, which will affect 1 in 4 people in their lifetime and is not reversible or curable. This technology is expected to regenerate the damaged heart tissue restoring heart function and improving life expectancy and quality of life.

CLXR-001 has successfully completed an EU Phase II clinical trial in which patients showed a statistically significant ( $P < 0.05$ ) improvement in all parameters including heart function, reduction in heart scarring and an improvement in quality of life.

**NAME OF AQSE CORPORATE ADVISER:**

First Sentinel Corporate Finance Limited

**NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:**

TBC

**SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):**

c. 28.30%

**SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT'S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:**

Shareholder's Name	Pre-Admission (%)	On Admission (%)
Ajan Reginald	22.15%	22.33%
The Sir Martin and Lady Judith Family Trust	14.05%	13.91%

Professor Sir Martin Evans	4.52%	4.86%
Mubasher Sheikh	10.33%	10.23%
Zita Sheikh	7.23%	7.16%
Kathryn Fallon	7.02%	3.18%
<b>TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:</b>		
N/A		
<b>THE EXPECTED ADMISSION DATE:</b>		
31 January 2025		
<b>WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:</b>		
Cardiogeni.com		